Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 759 results
Filters: First Letter Of Title is R  [Clear All Filters]
Found 759 results.

Adipose Tissue

Shikuma CM, Gangcuangco LMar A, Killebrew DA, et al. "The role of HIV and monocytes/macrophages in adipose tissue biology." J. Acquir. Immune Defic. Syndr.. 2014;65(2):151-9.

Adolescent

Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Simoni JM, Huh D, Wilson IB, et al. "Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study." J. Acquir. Immune Defic. Syndr.. 2012;60(5):466-72.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.

Adult

Evans SR, Simpson DM, Kitch DW, et al. "A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain." PLoS ONE. 2007;2(6):e551.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Riddler SA, Jiang H, Tenorio A, et al. "A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115." Antivir. Ther. (Lond.). 2007;12(4):531-41.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.
Wilkin TJ, McKinnon JE, A DiRienzo G, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes." J. Infect. Dis.. 2009;199(6):866-71.
Mwafongo A, Nkanaunena K, Zheng Y, et al. "Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine." AIDS. 2014;28(8):1135-42.
Grant PM, Komarow L, Andersen J, et al. "Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection." PLoS ONE. 2010;5(7):e11416.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Weinberg A, Bosch R, Bennett K, et al. "Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS." J. Acquir. Immune Defic. Syndr.. 2014;66(1):25-32.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Blodget E, Shen C, Aldrovandi G, et al. "Relationship between microbial translocation and endothelial function in HIV infected patients." PLoS ONE. 2012;7(8):e42624.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Luetkemeyer AF, Rosenkranz SL, Lu D, et al. "Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study." Clin. Infect. Dis.. 2013;57(4):586-93.

Pages